Get the Weekly Intelligence Brief — top committee picks every Sunday.
WAT · NYSE · STOCK

Waters (WAT) Stock Analysis

Healthcare Updated September 05, 2026
$409.37
52W $282.77 – $426.22
67/100
$30.93B
102.9
1.18
AI Committee Verdict
Buy
67/100
Conviction: Moderate · 60% agreement · 5 analysts
+0.1%
-16.1%
Moderate
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.

Is WAT Bullish or Bearish?

Bullish. Innellis AI committee rates Waters Corporation (WAT) Buy with a composite score of 67/100 , based on 5 analysts with 60% agreement. Last updated September 05, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +7.66 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -12.34 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull & Bear Case

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • MACD histogram negative -- bearish momentum — Technical
  • Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of September 05, 2026
Overall Committee Score
67/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 6%
of 192 Healthcare peers
Growth Analyst bullish
85 / 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst neutral
57 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst bullish
70 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
60 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3059.07)
Open Full Terminal →

Investment Thesis Evolution

Committee score strengthened significantly from 57.0 to 67.3.

Analyst-level changes:
  • Growth Analyst: score 63->85 (+22).
  • Value Analyst abstained (was bearish at 27).

Comparing 2026-09-04 to 2026-09-05 (1 day apart).

Technical Analysis

RSI (14)
54.6
Neutral
MACD Histogram
-1.417
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Lh Ll
Support
$346.83
Resistance
$413.85
Bollinger %B
0.59
Inside Bands
Price vs Moving Averages
EMA 9
$412.30 Below
EMA 21
$407.54 Above
EMA 50
$392.94 Above
EMA 200
$358.96 Above

Fundamental Analysis

Valuation
61
Growth
66
Profitability
74
Financial Health
94
Cash Flow
70
Valuation
P/E Ratio 102.9×
P/B Ratio 2.67×
PEG Ratio -1.61
Dividend Yield 0.00%
52W High $426.22
52W Low $282.77
Quality & Growth
ROE 2509.0%
ROA 1265.9%
Gross Margin 5078.3%
Operating Margin 796.0%
Revenue Growth YoY
Debt / Equity 0.35
AI Fundamental Assessment
P/E ratio of 102.9 (rich relative to a 15-40x range); Price-to-book of 2.7x; PEG ratio of -1.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 25.1%; Return on assets of 12.7%; Net margin of 3.6%; Gross margin of 50.8%; Current ratio of 1.86 (healthy short-term liquidity); Debt-to-equity of 0.35; Free cash flow per share is positive (4.06); Most recent quarter beat estimates by 0.4%; 2 consecutive earnings beats; EPS growth accelerating (-40.4% -> +13.0% QoQ); Average YoY EPS growth of 3.4%; Analyst estimates falling over recent quarters
Get the Full WAT Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime